StockNews.com Begins Coverage on Aethlon Medical (NASDAQ:AEMD)

Analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued on Friday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Aethlon Medical in a research report on Monday, March 10th.

Aethlon Medical Stock Performance

Shares of Aethlon Medical stock opened at $0.37 on Friday. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $1.79. The company has a fifty day moving average of $0.56 and a 200 day moving average of $0.50. The company has a market capitalization of $5.30 million, a P/E ratio of -0.23 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. Analysts forecast that Aethlon Medical will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Aethlon Medical

Several hedge funds have recently modified their holdings of the stock. Boothbay Fund Management LLC purchased a new stake in Aethlon Medical during the 4th quarter worth approximately $186,000. Virtu Financial LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth $81,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth $31,000. Allegiance Financial Group Advisory Services LLC purchased a new stake in shares of Aethlon Medical during the fourth quarter valued at $26,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Aethlon Medical in the 4th quarter valued at $25,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.